Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. cut its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 1.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,987,394 shares of the company’s stock after selling 167,357 shares during the period. Vanguard Group Inc. owned approximately 7.89% of Apellis Pharmaceuticals worth $226,015,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. ING Groep NV grew its holdings in Apellis Pharmaceuticals by 281.0% in the 3rd quarter. ING Groep NV now owns 1,174,500 shares of the company’s stock valued at $26,579,000 after buying an additional 866,200 shares in the last quarter. Profund Advisors LLC increased its position in Apellis Pharmaceuticals by 21.0% during the third quarter. Profund Advisors LLC now owns 34,712 shares of the company’s stock worth $786,000 after purchasing an additional 6,036 shares during the last quarter. Allianz Asset Management GmbH purchased a new position in Apellis Pharmaceuticals during the third quarter worth about $385,000. Jones Financial Companies Lllp boosted its holdings in Apellis Pharmaceuticals by 206.8% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after purchasing an additional 1,373 shares during the last quarter. Finally, Keybank National Association OH acquired a new stake in Apellis Pharmaceuticals during the third quarter worth $206,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insiders Place Their Bets

In related news, insider Mark Jeffrey Delong sold 3,371 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $73,386.67. Following the transaction, the insider directly owned 78,353 shares of the company’s stock, valued at approximately $1,705,744.81. This trade represents a 4.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pascal Deschatelets sold 5,928 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $129,052.56. Following the completion of the transaction, the insider directly owned 1,151,382 shares in the company, valued at approximately $25,065,586.14. This represents a 0.51% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 120,537 shares of company stock valued at $2,608,532 over the last quarter. 6.80% of the stock is owned by insiders.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock opened at $20.96 on Monday. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $30.48. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.70 and a current ratio of 3.14. The firm has a market cap of $2.68 billion, a PE ratio of 161.24 and a beta of 0.26. The firm’s 50-day simple moving average is $23.00 and its 200-day simple moving average is $23.77.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a return on equity of 8.20% and a net margin of 2.23%.The business had revenue of $199.91 million for the quarter, compared to the consensus estimate of $199.28 million. During the same quarter last year, the business posted ($0.29) EPS. The business’s revenue was down 5.9% on a year-over-year basis. Equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on APLS. Citigroup reduced their price target on shares of Apellis Pharmaceuticals from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. HC Wainwright raised their price target on Apellis Pharmaceuticals from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Cantor Fitzgerald lowered their target price on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a report on Tuesday, January 13th. Wells Fargo & Company reduced their price objective on shares of Apellis Pharmaceuticals from $29.00 to $26.00 and set an “overweight” rating for the company in a research note on Tuesday, January 20th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 29th. Twelve equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $32.61.

Apellis Pharmaceuticals News Summary

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright retains a “Buy” rating and a $48 price target, signaling continued analyst conviction in Apellis’ longer‑term upside. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
• Positive Sentiment: HC Wainwright published a long‑range forecast that includes a return to positive EPS by FY2030 (EPS ~$1.97), which underpins the firm’s $48 target and suggests expected recovery beyond the near term. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
• Neutral Sentiment: Apellis’ latest quarter delivered an EPS beat ($0.47 vs. expectations) but revenue was down ~6% year‑over‑year — a mixed fundamental print that reduces downside surprise risk but highlights demand pressure.
• Neutral Sentiment: Reported short‑interest data in recent filings appears anomalous (zero / NaN entries) and is not a reliable signal of investor positioning at this time.
• Negative Sentiment: HC Wainwright sharply lowered near‑term and multi‑year EPS forecasts (e.g., FY2026 cut to ~($2.19) from ($1.69); FY2027, FY2028 and several quarterly estimates were also reduced), increasing near‑term earnings uncertainty and pressuring the stock. HC Wainwright Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock
• Negative Sentiment: Citigroup trimmed its price target to $44, signaling reduced upside in the nearer term and contributing to downward pressure. Citigroup Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $44.00
• Negative Sentiment: Wedbush and Royal Bank of Canada also lowered expectations, adding to the analyst‑driven sell pressure. Wedbush Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Royal Bank Of Canada Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.